February 16, 2011
Otsuka Pharmaceutical Co., Ltd.
In-vitro Diagnostic Kit, WT1 mRNA Assay Kit 'Otsuka' Received Regulatory Approval for Additional Purpose of Use with Myelodysplastic Syndromes
Otsuka Pharmaceutical Co., Ltd. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Taro Iwamoto) today announced that it received regulatory approval for the additional purpose of use with myelodysplastic syndrome, for its WT1 mRNA Assay Kit "Otsuka," an in-vitro diagnostic kit, in Japan on February 14, 2011. WT1 mRNA Assay Kit "Otsuka" is already approved as a MRD monitoring marker for acute myeloid leukemia in Japan.
Information in this news release was current as of the original release date.